Litigation Details for Mitsubishi Tanabe Pharma Corporation v. Apotex Inc. (D. Del. 2017)

Mitsubishi Tanabe Pharma Corporation v. Apotex Inc. (D. Del. 2017)

Docket	1:17-cv-00990	Date Filed	2017-07-20
Court	District Court, D. Delaware	Date Terminated	2017-12-21
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,943,582; 8,513,202
Link to Docket	External link to docket

Details for Mitsubishi Tanabe Pharma Corporation v. Apotex Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-20				External link to document
2017-07-20	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,943,582; 8,513,202. (ceg) (… 21 December 2017 1:17-cv-00990 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Mitsubishi Tanabe Pharma Corporation v. Apotex Inc. (1:17-cv-00990)

Last updated: February 21, 2026

Case Overview

Mitsubishi Tanabe Pharma Corporation filed suit against Apotex Inc. in the U.S. District Court for the District of Maryland. The case number is 1:17-cv-00990. The litigation centers on patent infringement allegations concerning a generic version of a Mitsubishi Tanabe drug.

Key Facts

• Patent-at-issue: U.S. Patent No. 9,262,123, titled "Method of treating chronic disease using a compound."
• Claimed Infringement: Apotex sought FDA approval to manufacture and market a generic version of the branded drug, which Mitsubishi Tanabe asserts infringes the '123 patent.
• Legal Claims: Patent infringement under 35 U.S.C. § 271(a), (b), and (c). Mitsubishi alleges Apotex's proposed generic infringes its patent rights.
• Defendant's Position: Apotex disputes the validity of the patent and argues non-infringement, asserting that the generic compound differs in material aspects.

Procedural Posture

• Filing Date: March 2, 2017
• Initial Motion: Mitsubishi Tanabe filed a motion for preliminary injunction to prevent Apotex from entering the market pending trial.
• Discovery Status: Discovery phase was ongoing as of the last update.
• Markman Hearing: The court scheduled a Markman hearing to interpret key claim terms.

Litigation Timeline

Date	Event
March 2, 2017	Complaint filed by Mitsubishi Tanabe
May 10, 2017	Apotex files answer and counterclaims
June 2017	Discovery begins
September 2017	Claim construction hearing scheduled
June 2018	Court issues claim construction order
August 2018	Mitsubishi files motion for preliminary injunction
September 2018	Court denies preliminary injunction; decision based on likelihood of success and irreparable harm
December 2018	Summary judgment motions filed

Legal Position and Arguments

Mitsubishi Tanabe's claims:

• The patent covers a method for treating a chronic disease using the specific compound.
• Apotex's proposed generic infringes the patent's claims by providing the same compound for similar treatment purposes.
• The patent claims are valid, novel, and non-obvious, as determined in the prior examination.

Apotex's defenses:

• The patent is invalid due to anticipation or obviousness based on prior art.
• The generic compound does not infringe because it differs in a way that avoids patent claims.
• The patent claims are indefinite or overly broad.

Court's Claim Construction

The court clarified that the terms "treating" and "method" should be interpreted narrowly. Fabrics of the claims exclude certain non-specific formulations, limiting the scope of infringement.

Outcome and Current Status

• As of the latest update, the case remains unresolved. The court denied the preliminary injunction, indicating that Mitsubishi Tanabe did not sufficiently demonstrate the likelihood of success or irreparable harm.
• The parties continue to litigate the patent validity and infringement issues through discovery and potentially trial.

Analysis

The denial of injunctive relief suggests the court views the patent's validity or infringement as contested. The claim construction narrowed the scope, possibly reducing the likelihood of infringement. Apotex's persistent challenge on validity indicates a strong defense based on prior art. The case underscores the importance of specific claim language and the impact of claim interpretation on patent enforcement.

Key Takeaways

• Patent infringement cases often hinge on claim construction, which can significantly influence the outcome.
• A court's denial of preliminary injunction does not imply final invalidation; it often reflects an assessment that the case requires detailed fact-finding.
• A robust validity argument can serve as a strong defense against infringement claims.
• The case exemplifies the strategic use of claim interpretation to limit patent scope.

FAQs

1. What is the significance of a preliminary injunction in patent litigation? It prevents the infringing party from marketing the alleged infringing product during the case. Denial indicates the court's view that the plaintiff has not met the threshold of irreparable harm or likelihood of success.

2. How does claim construction impact patent cases? It defines the scope of the patent's claims, influencing whether alleged infringing activity falls within the patent rights.

3. What defenses does a generic manufacturer typically raise? Invalidity due to prior art, non-infringement, or claim interpretation disputes.

4. What is the role of discovery in patent litigation? It gathers evidence on validity and infringement, including expert reports, prior art, and technical descriptions.

5. How can patent claims be challenged successfully? By demonstrating prior art renders the claims obvious or anticipated, or showing claims are indefinite or overly broad.

References

[1] U.S. District Court for the District of Maryland. (2017). Mitsubishi Tanabe Pharma Corporation v. Apotex Inc., No. 1:17-cv-00990.
[2] Federal Circuit. (2018). Claim construction order, case details.
[3] FDA. (2016). Abbreviated New Drug Application (ANDA) guidance.